Non-Contrast-Enhanced Functional Lung MRI to Evaluate Treatment Response of Allergic Bronchopulmonary Aspergillosis in Patients With Cystic Fibrosis: A Pilot Study

被引:4
|
作者
Benlala, Ilyes [1 ,2 ,3 ,4 ,5 ,7 ]
Klaar, Rabea [1 ,2 ]
Gaass, Thomas [1 ,2 ]
Macey, Julie [4 ]
Bui, Stephanie [4 ]
De Senneville, Baudouin Denis [6 ]
Berger, Patrick [3 ,4 ]
Laurent, Francois [3 ,4 ]
Dournes, Gael [3 ,4 ]
Dinkel, Julien [1 ,2 ]
机构
[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiol, Munich, Germany
[2] Comprehens Pneumol Ctr CPC M, German Ctr Lung Research DZL, Munich, Germany
[3] Univ Bordeaux, Ctr Rech Cardiothorac Bordeaux, Pessac, France
[4] CHU Bordeaux, Serv Imagerie Thorac & Cardiovasc, Serv Explorat Fonct Respiratoire, Unite Pneumol Pediat,CIC 1401,Serv Malad Respirato, Pessac, France
[5] INSERM, Ctr Rech Cardiothorac Bordeaux, U1045, Pessac, France
[6] Univ Bordeaux, CNRS, Math Inst Bordeaux IMB, INRIA,Bordeaux INP,UMR 5251, Talence, France
[7] I B Hop Xavier Arnozan PTIB Ave Haut Leveque, F-33600 Pessac, France
关键词
ABPA; CF; ventilation; perfusion; Fourier decomposition; FOURIER DECOMPOSITION; COMPUTED-TOMOGRAPHY; PERFUSION; AIRWAY; CT; STANDARDIZATION; VENTILATION; VALIDATION;
D O I
10.1002/jmri.28844
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: Allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) patients is associated with severe lung damage and requires specific therapeutic management. Repeated imaging is recommended to both diagnose and follow-up response to treatment of ABPA in CF. However, high risk of cumulative radiation exposure requires evaluation of free-radiation techniques in the follow-up of CF patients with ABPA.Purpose: To evaluate whether Fourier decomposition (FD) functional lung MRI can detect response to treatment of ABPA in CF patients.Study Type: Retrospective longitudinal.Population: Twelve patients (7M, median-age:14 years) with CF and ABPA with pre-and post-treatment MRI.Field Strength/Sequence: 2D-balanced-steady-state free-precession (bSSFP) sequence with FD at 1.5T.Assessment: Ventilation-weighted (V) and perfusion-weighted (Q) maps were obtained after FD processing of 2D-coronal bSSFP time-resolved images acquired before and 3-9 months after treatment. Defects extent was assessed on the func-tional maps using a qualitative semi-quantitative score (0 = absence/negligible, 1 = <50%, 2 = >50%). Mean and coeffi-cient of variation (CV) of the ventilation signal-intensity (VSI) and the perfusion signal-intensity (QSI) were calculated. Measurements were performed independently by three readers and averaged. Inter-reader reproducibility of the measure-ments was assessed. Pulmonary function tests (PFTs) were performed within 1 week of both MRI studies as markers of the airflow-limitation severity.Statistical Tests: Comparisons of medians were performed using the paired Wilcoxon-test. Reproducibility was assessed using intraclass correlation coefficient (ICC). Correlations between MRI and PFT parameters were assessed using the Spearman-test (rho correlation-coefficient). A P-value <0.05 was considered as significant.Results: Defects extent on both V and Q maps showed a significant reduction after ABPA treatment (4.25 vs. 1.92 for V-defect-score and 5 vs. 2.75 for Q-defect-score). VSI_mean was significantly increased after treatment (280 vs. 167). Qualitative analyses reproducibility showed an ICC > 0.90, while the ICCs of the quantitative measurements was almost perfect (>0.99). Changes in VSI_cv and QSI_cv before and after treatment correlated inversely with changes of FEV1%p (rho =-0.68 for both).Data Conclusion: Non-contrast-enhanced FD lung MRI has potential to reproducibly assess response to treatment of ABPA in CF patients and correlates with PFT obstructive parameters.
引用
收藏
页码:909 / 919
页数:11
相关论文
共 46 条
  • [41] Phase I dose escalation, toxicity and dynamic contrast-enhanced (DCE) MRI imaging biomarker study of first line treatment with imatinib (I) and cisplatin (C) plus docetaxel (D) in patients with advanced non-small cell lung cancer (NSCLC)
    Vlahovic, G.
    Foster, T. L.
    Andrews, C. H.
    Herndon, J. E., II
    Sporn, T.
    Kelley, M. J.
    Dewhirst, M. W.
    Vujaskovic, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Dynamic contrast-enhanced MRI to predict response to vinorelbine-cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial
    Zhang, Rui
    Wang, Zhi-Yu
    Li, Yue-Hua
    Lu, Yao-Hong
    Wang, Shuai
    Yu, Wen-Xi
    Zhao, Hui
    LANCET, 2016, 388 : 95 - 95
  • [43] Screening for brain metastases (BM) in patients (pts) with stage III non-small cell lung cancer (NSCLC), magnetic resonance imaging (MRI) or dedicated contrast-enhanced computed tomography (dCE-CT)? A prospective observational study
    Schoenmaekers, J. J. A. O.
    Hendriks, L.
    Dingemans, A-M. C.
    De Ruysscher, D.
    Bootsma, G.
    Schreurs, W.
    Westenend, M.
    Houben, R.
    Hofman, P.
    De Booij, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [44] Quantification of Anti-Angiogenic Effect of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) with Dynamic Contrast-Enhanced MR Imaging (DCE-MRI) in Patients with Non-Small Cell Lung Cancer (NSCLC) Feasibility Study
    Yi, Chin A.
    Lee, Ju Won
    Kim, Jae-Hun
    Park, Keunchil
    Ahn, Myung-Ju
    Kim, Seonwoo
    Lee, Kyung Soo
    Lee, Ho Yun
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S384 - S384
  • [45] ECOG 3503: A pilot study to determine if downstream markers of EGFR linked signaling pathways predict response to erlotinib (OSI-774) in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC).
    Kolesar, J.
    Brahmer, J.
    Li, S.
    Guaglianone, P.
    Patel, J.
    Keppen, M.
    Hidalgo, M.
    Carbone, D.
    Siegfried, J.
    Schiller, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 404S - 404S
  • [46] Final results of ECOG 3503: A pilot study to determine if downstream markers of EGFR linked signaling pathways predict response to erlotinib (OSI-774) in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
    Kolesar, J.
    Brahmer, J.
    Lee, J.
    Guaglianone, P.
    Patel, J.
    Keppen, M.
    Hidalgo, M.
    Carbone, D.
    Schiller, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)